La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Alector Gestione

Gestione criteri di controllo 2/4

Alector's Il CEO è Arnon Rosenthal, nominato in Jan2013, e ha un mandato di 11.58 anni. la retribuzione annua totale è $ 4.26M, composta da 15.4% di stipendio e 84.6% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 5.67% delle azioni della società, per un valore di $ 28.91M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.6 anni e 5.4 anni.

Informazioni chiave

Arnon Rosenthal

Amministratore delegato

US$4.3m

Compenso totale

Percentuale dello stipendio del CEO	15.4%
Mandato del CEO	11.6yrs
Proprietà del CEO	5.7%
Durata media del management	2.6yrs
Durata media del Consiglio di amministrazione	5.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Alector, Inc.'s (NASDAQ:ALEC) Price Is Right But Growth Is Lacking

Jul 11

Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 11

Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results

Mar 01

The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 27%

Jan 19

Alector: Good Data, Huge Cash, No Near Term Catalyst

Jan 16

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Sep 25

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Jun 27

Analysts Are Betting On Alector, Inc. (NASDAQ:ALEC) With A Big Upgrade This Week

Mar 02

Need To Know: The Consensus Just Cut Its Alector, Inc. (NASDAQ:ALEC) Estimates For 2022

May 18

Alector: Expect Phase 3 Data Next Year

Apr 16

These Analysts Just Made An Downgrade To Their Alector, Inc. (NASDAQ:ALEC) EPS Forecasts

Feb 27

Alector, Inc: A Newer Biotech Company With Big Potential

Jan 26

Alector: The GSK Deal Is A Major Value Add

Oct 29

We're Not Very Worried About Alector's (NASDAQ:ALEC) Cash Burn Rate

Sep 27

This Just In: Analysts Are Boosting Their Alector, Inc. (NASDAQ:ALEC) Outlook for This Year

Aug 05

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Arnon Rosenthal rispetto agli utili di Alector?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-US$161m
Mar 31 2024	n/a	n/a	-US$121m
Dec 31 2023	US$4m	US$654k	-US$130m
Sep 30 2023	n/a	n/a	-US$141m
Jun 30 2023	n/a	n/a	-US$143m
Mar 31 2023	n/a	n/a	-US$135m
Dec 31 2022	US$4m	US$621k	-US$133m
Sep 30 2022	n/a	n/a	-US$136m
Jun 30 2022	n/a	n/a	US$36m
Mar 31 2022	n/a	n/a	-US$29m
Dec 31 2021	US$10m	US$575k	-US$36m
Sep 30 2021	n/a	n/a	-US$33m
Jun 30 2021	n/a	n/a	-US$212m
Mar 31 2021	n/a	n/a	-US$202m
Dec 31 2020	US$4m	US$554k	-US$190m
Sep 30 2020	n/a	n/a	-US$169m
Jun 30 2020	n/a	n/a	-US$148m
Mar 31 2020	n/a	n/a	-US$127m
Dec 31 2019	US$7m	US$525k	-US$105m
Sep 30 2019	n/a	n/a	-US$92m
Jun 30 2019	n/a	n/a	-US$76m
Mar 31 2019	n/a	n/a	-US$62m
Dec 31 2018	US$5m	US$397k	-US$52m
Sep 30 2018	n/a	n/a	-US$45m
Jun 30 2018	n/a	n/a	-US$39m
Mar 31 2018	n/a	n/a	-US$35m
Dec 31 2017	US$3m	US$370k	-US$32m

Compensazione vs Mercato: La retribuzione totale di Arnon ($USD 4.26M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 2.44M ).

Compensazione vs guadagni: La retribuzione di Arnon è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Arnon Rosenthal (68 yo)

11.6yrs

Mandato

US$4,255,007

Compensazione

Dr. Arnon Rosenthal, Ph D., Co-Founded Annexon in 2013 and serves as its Chief Executive Officer and Director since 2013 and served as its President since 2013. He served as Chief Scientific Officer of Ale...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Arnon Rosenthal	Co-Founder	11.6yrs	US$4.26m	5.67% $ 28.9m
Saraswati Kenkare-Mitra	President and Head of Research & Development	2.7yrs	US$2.61m	0.13% $ 670.8k
Marc Grasso	CFO, Principal Financial Officer & Principal Accounting Officer	2.5yrs	US$1.72m	0.029% $ 146.4k
Gary Romano	Chief Medical Officer	2.3yrs	US$1.62m	0.068% $ 348.5k
Peter Heutink	Chief Scientific Officer	2.6yrs	Nessun dato	Nessun dato
Katie Hogan	Senior Director of Corporate Communication & Investor Relations	no data	Nessun dato	Nessun dato
Danielle Pasqualone	General Counsel	2.6yrs	Nessun dato	Nessun dato
Clare Hunt	Chief People Officer	no data	Nessun dato	Nessun dato
Kristina Cutter	Chief Regulatory	no data	Nessun dato	Nessun dato
Virginia DeJesus-Rueff	Chief of Staff & Head of Strategy	2.6yrs	Nessun dato	Nessun dato
Norah Conway	Senior Vice President of Portfolio & Program Management	2.6yrs	Nessun dato	Nessun dato
Neil Berkley	Chief Business Officer	less than a year	Nessun dato	Nessun dato

2.6yrs

Durata media

56yo

Età media

Gestione esperta: Il team dirigenziale di ALEC è considerato esperto (durata media dell'incarico 2.6 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Arnon Rosenthal	Co-Founder	11.6yrs	US$4.26m	5.67% $ 28.9m
Louis Lavigne	Independent Chairperson of the Board	5.8yrs	US$355.07k	0.037% $ 187.1k
Richard Scheller	Director & Member of Scientific Advisory Board	5.8yrs	US$509.13k	0.045% $ 231.9k
Thomas Sudhof	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Stephen Hauser	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
David Wehner	Independent Director	5.8yrs	US$324.71k	0.083% $ 420.9k
Adam Boxer	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Paula Hammond	Independent Director	4.4yrs	US$318.92k	0.026% $ 132.1k
Kristine Yaffe	Independent Director	5yrs	US$318.12k	0.034% $ 171.4k
Michael Heneka	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Martin Kampmann	Member of Scientific Advisory Board	2.6yrs	Nessun dato	Nessun dato
Elizabeth Garofalo	Independent Director	2.9yrs	US$322.27k	0.027% $ 137.5k

5.4yrs

Durata media

67yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ALEC sono considerati esperti (durata media dell'incarico 5.4 anni).

Alector Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Co-Founder recently sold US$121k worth of stock

Co-Founder notifies of intention to sell stock

Alector, Inc., Annual General Meeting, Jun 12, 2024

Co-Founder recently sold US$130k worth of stock

Co-Founder notifies of intention to sell stock

Insufficient new directors

Recent updates

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)

Alector, Inc.'s (NASDAQ:ALEC) Price Is Right But Growth Is Lacking

Co-Founder recently sold US$121k worth of stock

Co-Founder notifies of intention to sell stock

Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Alector, Inc. Reiterates Revenue Guidance for the Year Ending 2024

First quarter 2024 earnings released: US$0.39 loss per share (vs US$0.55 loss in 1Q 2023)

Alector, Inc., Annual General Meeting, Jun 12, 2024

Co-Founder recently sold US$130k worth of stock

Consensus revenue estimates decrease by 37%, EPS upgraded

Co-Founder notifies of intention to sell stock

Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results

Alector, Inc. Provides Revenue Guidance for the Year Ending 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Alector Announces First Patient Dosed in Progress-Ad Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’S Disease

The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 27%

Alector, Inc. has completed a Follow-on Equity Offering in the amount of $71.413049 million.

New minor risk - Shareholder dilution

Alector, Inc. has completed a Follow-on Equity Offering in the amount of $75 million.

Alector: Good Data, Huge Cash, No Near Term Catalyst

Insufficient new directors

New major risk - Revenue and earnings growth

Co-Founder recently sold US$133k worth of stock

Co-Founder notifies of intention to sell stock

Alector, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Alector, Inc. Reiterates Earnings Guidance for the Year Ending 2023

Alector, Inc. Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to Progranulin Gene Mutation (FTD-GRN)

Price target decreased by 12% to US$15.40

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Alector, Inc. Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002

Consensus revenue estimates increase by 244%

New minor risk - Share price stability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Price target decreased by 13% to US$14.33

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. Provides Revenue Guidance for the Year 2023

Co-Founder recently sold US$94k worth of stock

Consensus revenue estimates decrease by 24%

Consensus revenue estimates fall by 79%

Key Executive recently sold US$84k worth of stock

Price target decreased by 20% to US$16.94

Analysts Are Betting On Alector, Inc. (NASDAQ:ALEC) With A Big Upgrade This Week

Full year 2022 earnings released: US$1.62 loss per share (vs US$0.45 loss in FY 2021)

Alector (NASDAQ:ALEC) Is In A Good Position To Deliver On Growth Plans

Price target decreased to US$21.44

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Alector, Inc. Announces Promotion of Clare Hunt to Chief People Officer

Alector, Inc. Announces Resignation of Robert King as Chief Development Officer

Alector: Advancement Of Third Alzheimer's Drug Brings About Huge Potential

Alector, Inc. Initiates Phase 1 Clinical Trial of Al044 for the Treatment of Alzheimer’s Disease

Consensus revenue estimates increase by 13%

Price target decreased to US$24.96

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Alector, Inc Developing AL003 to Treat Patients with Alzheimer's Disease as One of Two Programs Pursuant to the Co-Development and Option Agreement

AbbVie ends partnership with Alector for Alzheimer’s candidate

Alector: Potential In Neurology And Cancer Treatments

Price target decreased to US$28.59

Need To Know: The Consensus Just Cut Its Alector, Inc. (NASDAQ:ALEC) Estimates For 2022

Consensus revenue estimates fall by 26%

Price target decreased to US$31.26

First quarter 2022 earnings: EPS and revenues miss analyst expectations